Epigenomics Files Third Module of PMA to FDA for Colon Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today announced it has submitted the third of four modules to US regulators for possible approval of its Epi proColon blood-based colorectal cancer screening test.

The German molecular diagnostics company said it expects to submit the fourth and final module to the US Food and Drug Administration in the second half of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.